Targeting other surface proteins, such as prostate stem cell antigen (refs. 65, 66; NCT03927573, NCT03873805) and TROP2 (ref. 67; NCT04152499) are also in development in prostate cancer. Here, TACSTD2 is linked to prostate carcinoma.